Farmaceutica Remedia (LTS:0M8I) 1-Year Sharpe Ratio: -79.68 (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M8I Farmaceutica Remedia SA LTS:0M8I
61 GF Score
Price lei0.25
GF Value lei0.24
! 11 Warning Signs
View Full Analysis

What is Farmaceutica Remedia 1-Year Sharpe Ratio?

Farmaceutica Remedia LTS:0M8I 61 1-Year Sharpe Ratio is -79.68 as of Sep. 21, 2026. GuruFocus rates LTS:0M8I with a GF Score™ of 61/100 and a GF Value™ of lei0.24. The stock has 11 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-21), Farmaceutica Remedia's 1-Year Sharpe Ratio is -79.68.

Farmaceutica Remedia  (LTS:0M8I) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Farmaceutica Remedia 1-Year Sharpe Ratio Related Terms

LTS:0M8I vs MCK, COR, CAH: 1-Year Sharpe Ratio Comparison

For the Medical Distribution subindustry, Farmaceutica Remedia's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Farmaceutica Remedia 1-Year Sharpe Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Farmaceutica Remedia's 1-Year Sharpe Ratio falls into.


LTS:0M8I
61GF Score
Farmaceutica Remedia SA LTS:0M8I
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Farmaceutica Remedia 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -79.68 mean?
Farmaceutica Remedia (LTS:0M8I) has a 1-Year Sharpe Ratio of -79.68 as of Sep. 21, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Farmaceutica Remedia and its competitors.
Is Farmaceutica Remedia's 1-Year Sharpe Ratio too high?
Farmaceutica Remedia's current 1-Year Sharpe Ratio is -79.68. Overall, Farmaceutica Remedia has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's 1-Year Sharpe Ratio compare to MCK and COR?
Farmaceutica Remedia's 1-Year Sharpe Ratio of -79.68 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Distribution company?
A good 1-Year Sharpe Ratio depends on the Medical Distribution industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current 1-Year Sharpe Ratio is -79.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current 1-Year Sharpe Ratio of -79.68. The stock's GF Value™ is lei0.24, compared to a current price of lei0.25 — trading 4.2% above its estimated fair value. The current 1-Year Sharpe Ratio is -79.68. Farmaceutica Remedia's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current 1-Year Sharpe Ratio is -79.68 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?

Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued. The current stock price of lei0.25 is trading 4.2% above its estimated GF Value™ of lei0.24.

Key valuation signals for LTS:0M8I:

  • 1-Year Sharpe Ratio: -79.68
  • GF Value™: lei0.24 vs. price of lei0.25 (4.2% above fair value)
  • GF Score™: 61/100 with 11 warning signs

No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Farmaceutica Remedia Business Description

Other Exchanges RMAH:Romania
Address No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
61GF Score

Get the complete analysis for LTS:0M8I

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.25
Price
lei0.24
GF Value